% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Palmedo:277292,
      author       = {H. Palmedo and H. Ahmadzadehfar and S. Eschmann and A.
                      Niesen and J. Schönberger and V. Barsegian and K. Liepe and
                      F. M. Mottaghy and R. Guan and J. Pinkert and P. Sandström
                      and K. Herrmann$^*$},
      title        = {{P}ain {O}utcomes in {P}atients with {M}etastatic
                      {C}astration-{R}esistant {P}rostate {C}ancer {T}reated with
                      223{R}a: {PARABO}, a {P}rospective, {N}oninterventional
                      {S}tudy.},
      journal      = {Journal of nuclear medicine},
      volume       = {64},
      number       = {9},
      issn         = {0097-9058},
      address      = {New York, NY},
      publisher    = {Soc.},
      reportid     = {DKFZ-2023-01321},
      pages        = {1392-1398},
      year         = {2023},
      note         = {2023 Sep;64(9):1392-1398},
      abstract     = {223Ra, a targeted α-therapy, is approved for the treatment
                      of patients with metastatic castration-resistant prostate
                      cancer (mCRPC) who have bone metastases. In the phase 3
                      ALSYMPCA study, 223Ra prolonged survival and improved
                      quality of life versus placebo. Our real-world study,
                      PARABO, investigated pain and bone pain-related quality of
                      life in patients with mCRPC and symptomatic bone metastases
                      receiving 223Ra in clinical practice. Methods: PARABO was a
                      prospective, observational, noninterventional single-arm
                      study conducted in nuclear medicine centers across Germany
                      (NCT02398526). The primary endpoint was a clinically
                      meaningful pain response (≥2-point improvement from
                      baseline for the worst-pain item score in the Brief Pain
                      Inventory-Short Form). Results: The analysis included 354
                      patients, who received a median of 6 223Ra injections
                      (range, 1-6). Sixty-seven percent (236/354) received 5-6
                      injections, and $33\%$ (118/354) received 1-4 injections. Of
                      216 patients with a baseline worst-pain score of more than
                      1, $59\%$ (128) had a clinically meaningful pain response
                      during treatment. Corresponding rates were $67\%$ (range,
                      98/146) with 5-6 223Ra injections versus $43\%$ (range,
                      30/70) with 1-4 injections, $60\%$ (range, 60/100) in
                      patients with no more than 20 lesions versus $59\%$ (range,
                      65/111) in those with more than 20 lesions, and $65\%$
                      (range, 69/106) in patients without prior or concomitant
                      opioid use versus $54\%$ (range, 59/110) in those with prior
                      or concomitant opioid use. Mean subscale scores (pain
                      severity and pain interference) on the Brief Pain
                      Inventory-Short Form improved during treatment. Conclusion:
                      223Ra reduced pain in patients with mCRPC and symptomatic
                      bone metastases, particularly in patients who received 5-6
                      injections. The extent of metastatic disease did not impact
                      pain response.},
      keywords     = {223Ra (Other) / bone metastases (Other) /
                      castration-resistant prostate cancer (Other) / pain response
                      (Other) / targeted α-therapy (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37385670},
      doi          = {10.2967/jnumed.123.265557},
      url          = {https://inrepo02.dkfz.de/record/277292},
}